Denis McCarthy, MD
Professor of Medicine
Division of Gastroenterology
University of New Mexico
Albuquerque, New Mexico
Michael Slyk, Pharm D, FASCP
Pharmacotherapy Associates Inc.
Affiliate Associate Professor of Pharmacy
University of Toledo College of Pharmacy
CREDIT FOR THIS PROGRAM IS AVAILABLE FOR PHARMACISTS ONLY.
Gastroesophageal reflux disease affects over 75% of the American population, and can be associated with anything from mildly bothersome symptoms to severe symptoms that interfere with daily living. The long-term care patient in particular represents a special challenge, in that they often cannot be treated the same way as a typical ambulatory patient who is not in a long-term care facility. The long-term care patient is often bedridden, sometimes unable to take oral medications, sometimes mentally impaired and usually on a variety of concomitant medications for a variety of concomitant medical conditions. The pharmacologic and nonpharmacologic therapies for the long-term care patient may differ substantially from that of the ordinary patient. Additionally, the differential diagnosis of GERD in this patient population may be particularly challenging given the high frequency of other disorders and overlapping symptoms or atypical presentations. Program Developer/Facilitator
. Target Audience
Consultant pharmacists interested in the management of GERD in long-term care patients
Upon completion of this educational activity, the participant should be able to:
Discuss the pathophysiology of GERD and its nocturnal manifestations in elderly persons and long-term care patients.
Identify symptomatology and the possible multiple presentations of GERD in the elderly patient in long-term care, and be able to make differential diagnoses in the patient with multiple complaints and disabilities.
Describe pharmacologic and nonpharmacologic approaches to treating GERD and discuss how these may impact other medical conditions in long-term care patients.
Dr. McCarthy is an occasional speaker for and is on the Scientific Advisory Boards for AstraZeneca, Boehringer-Ingelheim Pharmaceuticals, Inc., Byr-Gulden Inc., Forest Laboratories, Janssen Pharmaceutica Inc., and Wyeth Pharmaceuticals.
Dr. Slyk has received honoraria, research grants, educational grants or consulting fees from Eli Lilly and Company, Janssen Pharmaceutica Inc., Merck and Co., Inc., Novartis Pharmaceutical, Organon, Ortho-McNeil Pharmaceutical, Pfizer Inc, Pharmacia & Upjohn, Inc., Schering-Plough Corporation and Wyeth Pharmaceuticals.
Faculty intend to discuss off label or investigational uses of certain drugs, which will be clearly identified within the program. Credit Statements
This program was developed by the American Society of Consultant Pharmacists (ASCP) and is approved for 2.0 Contact Hours (0.2 CEU). ASCP is approved by the American Council on Pharmaceutical Education (ACPE) as a provider of continuing pharmaceutical education.
A Statement of Credit will be mailed upon successful completion of the post-test with a score of 70% or better.
Commercial Support Statements
This program is supported by an unrestricted educational grant from
Click on the "Start program" icon.
The next screen will permit you to check for or download Flash, required to run this program. You will also find buttons which will permit you to start the program presentation, access other program elements, and take the post-test.
Clicking on "start the program" on this screen will begin the program presentation which will take approximately 2 hours to complete.
You must be registered with cmecorner.com in order to complete the post-test. When you click on the post-test button you will be brought to a screen which will confirm your registration status and provide an opportunity to register if you haven't done so previously.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a Statement of Credit.
The information contained in this program does not necessarily reflect the opinions or recommendations of Wyeth Pharmaceuticals, the American Society of Consultant Pharmacists, or Medical Communications Media, Inc. Diagnostic procedures or treatments discussed in the program should not be utilized by clinicians without evaluation of patients’ conditions and possible contraindications or risks, and without a review of applicable manufacturer’s product information and comparison with recommendations of other authorities.